News | Peripheral Artery Disease (PAD) | February 15, 2022

Alkem Licenses Technology from Harvard University, Aiming to Treat Ischemic Injury and Vascular Diseases

Novel delivery of established growth and neurotropic factors developed at Wyss Institute enables local, sustained release for greater efficacy.

The licensed technology involves the use of a proprietary hydrogel developed at the Wyss Institute to deliver human growth factors that have regenerative properties directly to the site of injury, dramatically prolonging the duration of effect and reducing the dose required. Credit: Wyss Institute at Harvard University


February 15, 2022 Alkem Laboratories Limited (Alkem), an Indian multinational pharmaceutical company, has signed a license agreement with Harvard University’s Office of Technology Development (OTD) enabling Alkem to develop and commercialize a novel technology that may help meet the dire need for effective treatment of diabetic neuropathy, foot ulcers, peripheral arterial disease (PAD), and other injuries caused by vascular disease. Developed in the lab of Dave Mooney, Ph.D. at Harvard’s Wyss Institute for Biologically Inspired Engineering and John A. Paulson School of Engineering and Applied Sciences (SEAS), the technology is an injectable, biocompatible scaffold for the sustained release of tissue-regenerative molecules. Alkem plans to apply its drug development and manufacturing capability to advance this technology from bench to bedside through the application of efficient translational, pre-clinical, and clinical models.

“This license agreement with Harvard enables us to harness an innovation with great clinical potential, identified and nurtured by the Wyss Institute, to bring novel treatments to market. It also serves as an example of Alkem’s commitment to fostering continued academic, clinical, and commercial collaborations to bring impactful medical technologies to patients,” said Alkem’s Managing Director, Sandeep Singh. Alkem’s President and Chief Medical Officer, Akhilesh Sharma added, “This technology’s novel, regenerative medicine approach could help fill a therapy gap in the treatment of multiple causes of ischemic tissue injuries, with the potential to avoid several thousands of foot deformities and amputations and provide relief from other ischemic conditions.”  

The license grants Alkem commercialization rights in the United States and India.

Donald Ingber, M.D., Ph.D., the Wyss Institute’s Founding Director, said, “This technology license represents yet another successful initiative by the Wyss Institute to advance our mission of bringing lifesaving technologies out of the lab and into the real world. Alkem’s position in India gives it the potential to reach many millions of patients who do not have access to expensive, brand-name treatments, which could significantly contribute to the reduction of human suffering globally.” Ingber is the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and Professor of Bioengineering at Harvard SEAS.

A new solution to enable regenerative medicine

Tissue regenerative molecules are naturally occurring biomolecules in the human body that are known to help enhance tissue regrowth after injury or chronic disease. Despite their therapeutic promise, these biologics have not yet been developed into FDA-approved treatments because they are very rapidly cleared from the body, which dramatically reduces their efficacy. Furthermore, because of the high doses required to overcome the clearance challenge, there has been concern that these treatments could cause toxicity when administered to patients orally or via injection.  

To solve this problem, researchers led by Mooney, a Wyss Core Faculty member and the Robert P. Pinkas Family Professor of Bioengineering at Harvard SEAS, developed a technique that encapsulates two tissue regenerative molecules into a biocompatible, precisely designed scaffold that is injected under the skin at the site of ischemia and injury. The scaffold allows the molecules to be released in a sustained manner over time, which enables tissue regeneration at very low doses.

Initiated as a collaboration between researchers at Harvard SEAS and the Wyss Institute, the technology advanced through development and de-risking at the Wyss Institute to demonstrate proof-of-concept. Preclinical studies conducted at the Wyss Institute demonstrated that blood perfusion recovered to 80–90% while muscle strength was restored to pre-injury levels after a few weeks of the treatment, which also reversed nerve damage. This precision, novel enabling technology went through a thorough diligence process with Alkem, who were impressed by its potential use in populations worldwide to treat multiple ischemic conditions.

“Scientists can point to many promising treatments for diseases and injuries that have never made it to the clinic, not because they don’t work, but because delivering them via a classic injection or pill wasn’t possible,” said Mooney. “I’m hopeful that our success in solving that problem for these tissue regenerative biomolecules will inspire others in academia and industry to revisit some of those ‘difficult’ drugs and make them available for more patients around the world.”

Related Content

News | Peripheral Artery Disease (PAD)

June 13, 2022 — Royal Philips announced the latest results from the Tack Optimized Balloon Angioplasty (TOBA) II below ...

Home June 13, 2022
Home
News | Peripheral Artery Disease (PAD)

May 20, 2022 — New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel ...

Home May 20, 2022
Home
News | Peripheral Artery Disease (PAD)

May 19, 2022 — One year outcomes from the Disrupt PAD III Trial comparing intravascular lithotripsy (IVL) with a drug ...

Home May 19, 2022
Home
News | Peripheral Artery Disease (PAD)

March 22, 2022 – With 60 years of experience, The Cardiovascular Care Group is nationally recognized for vascular and ...

Home March 22, 2022
Home
News | Peripheral Artery Disease (PAD)
February 21, 2022 – A research group the Department of Cardiovascular Medicine, Osaka City University Graduate School of ...
Home February 21, 2022
Home
News | Peripheral Artery Disease (PAD)

January 17, 2022 – The Vascular Care Group (TVCG) announced Stephen J. Hoenig M.D., successfully completed a ...

Home January 17, 2022
Home
News | Peripheral Artery Disease (PAD)

October 20, 2021 — Boston Scientific Corporation announced positive data for the Eluvia Drug-Eluting Vascular Stent ...

Home October 20, 2021
Home
News | Peripheral Artery Disease (PAD)

June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery ...

Home June 07, 2021
Home
News | Peripheral Artery Disease (PAD)

May 17, 2021 — The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the ...

Home May 17, 2021
Home
News | Peripheral Artery Disease (PAD)

January 26, 2021 — Pedra Technology, a privately held company, announced today that the U.S. Food and Drug ...

Home January 26, 2021
Home
Subscribe Now